Disis et al. demonstrated that immunization with 100 μg of the HER2 ICD plasmid-based vaccine was associated with the generation of HER2-specific Th1 cells in most patients with HER2-expressing breast cancer, and it is currently being evaluated in a randomized phase 2 trial [430]. This evidence concerns the gene ERBB2 and breast carcinoma.